Related Experiment Videos
Abstract:
The incidence of Candida meningitis in the neonatal period is increasing, and 63% of reported patients have either died or are mentally retarded. We report a newborn with Candida meningitis and arthritis who did well after treatment with intravenous and intrathecal amphotericin B, along with oral flucytosine.
Insights
Candida meningitis is a growing concern in newborns, often leading to severe outcomes. This case highlights successful treatment of neonatal Candida meningitis and arthritis using amphotericin B and flucytosine.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Mycology
Background:
- Neonatal meningitis caused by Candida species presents a significant and increasing public health challenge.
- High mortality and severe neurological sequelae (63%) are associated with invasive Candida infections in neonates.
Observation:
- A newborn infant presented with a confirmed diagnosis of Candida meningitis and concurrent arthritis.
- The clinical presentation indicated a severe invasive fungal infection in a vulnerable neonatal patient.
Findings:
- The neonate received a combination therapy including intravenous and intrathecal amphotericin B.
- Oral flucytosine was administered as an adjunct to the antifungal regimen.
- The patient demonstrated a positive clinical response and recovery following the prescribed treatment.
Implications:
- This case underscores the efficacy of combined antifungal therapy (amphotericin B and flucytosine) in treating neonatal Candida meningitis and arthritis.
- Successful management of such severe invasive fungal infections can improve neonatal outcomes, reducing mortality and long-term disability.
- The findings support the use of intrathecal amphotericin B in severe neonatal meningitis cases where systemic treatment alone may be insufficient.